Phase I expansion study of XMT-1536, a novel NaPi2b-targeting ADC – Preliminary results in Pts with previously treated metastatic OC or NSCLC – Debra L. Richardson MD – Sarah Cannon @Sara…

Debra L. Richardson, MD – Sarah Cannon discusses Phase I expansion study of XMT-1536, a novel NaPi2b-targeting antibody-drug conjugate (ADC): Preliminary efficacy, safety, and biomarker results in patients with previously treated metastatic ovarian cancer (OC) or non-small cell lung cancer (NSCLC)

ASCO

https://meetinglibrary.asco.org/record/188449/abstract